Zobrazeno 1 - 10
of 177
pro vyhledávání: '"Craig L, Leonardi"'
Publikováno v:
JAAD Case Reports, Vol 27, Iss , Pp 128-130 (2022)
Externí odkaz:
https://doaj.org/article/f1e8280d3b6d4c599330c36e5e6f7952
Autor:
Wayne P. Gulliver, Kyoungah See, Baojin Zhu, Bruce W. Konicek, Ryan W. Harrison, Robert R. McLean, Samantha J. Kerti, Russel T. Burge, Craig L. Leonardi
Publikováno v:
Journal of Psoriasis and Psoriatic Arthritis. 8:74-82
Background Dermatologists would benefit from an easy to use psoriasis severity assessment tool in the clinic. Objective To develop psoriasis assessment tools to predict PASI and Dermatology Life Quality Index (DLQI) using simple measures typically co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a44ed90c619130e47a96d06196b0ed01
https://doi.org/10.1177/24755303231155118
https://doi.org/10.1177/24755303231155118
Autor:
Bruce E. Strober, Joelle M. van der Walt, April W. Armstrong, Marc Bourcier, Andre V. E. Carvalho, Edgardo Chouela, Arnon D. Cohen, Claudia de la Cruz, Charles N. Ellis, Andrew Y. Finlay, Alice B. Gottlieb, Johann E. Gudjonsson, Lars Iversen, C. Elise Kleyn, Craig L. Leonardi, Charles W. Lynde, Caitriona Ryan, Colin T. Theng, Fernando Valenzuela, Ronald Vender, Jashin J. Wu, Helen S. Young, Alexa B. Kimball
Publikováno v:
Dermatology and Therapy, Vol 9, Iss 1, Pp 5-18 (2018)
Abstract Engaging global key opinion leaders, the International Psoriasis Council (IPC) held a day-long roundtable discussion with the primary purpose to discuss the treatment goals of psoriasis patients and worldwide barriers to optimal care. Settin
Externí odkaz:
https://doaj.org/article/ee5c476d90bb43d4bc632f02137fee65
Autor:
Craig L. Leonardi, Kyoungah See, Russel Burge, Zhuoer Sun, Ying Zhang, Lotus Mallbris, Alyssa Garrelts, Richard B. Warren
Publikováno v:
Advances in Therapy. 39:2256-2269
Number needed to treat (NNT) estimates are a practical metric to help identify the most effective therapies. Our objective is to compare 11 biologic drugs for moderate-to-severe psoriasis in terms of NNT.The NNT data were obtained from a Bayesian net
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78c4490b91396ebbf959d491cee1b394
https://doi.org/10.1007/s12325-022-02065-w
https://doi.org/10.1007/s12325-022-02065-w
Autor:
Sisi Wang, William N Malatestinic, Craig L. Leonardi, Baojin Zhu, Russel Burge, Rei Tao, Solmaz Setayeshgar
Publikováno v:
Journal of Dermatological Treatment. 33:2278-2284
Objective To assess treatment patterns of Ixekizumab (IXE) and evaluate the speed of onset and long-term clinical and quality-of-life outcomes among a subset of patients who switched from adalimumab (ADA) and secukinumab (SEC) to IXE in a real-world
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::351c378f5e545d32ff8865b291976172
https://doi.org/10.1080/09546634.2021.1952154
https://doi.org/10.1080/09546634.2021.1952154
Autor:
Nirali Kotowsky, Steven R. Feldman, Rhonda L Bohn, Ran Gao, Jeffrey M. Sobell, Erin O. Comerford, Amanda K. Golembesky, Elizabeth M. Garry, Wendell C. Valdecantos, Craig L. Leonardi
Publikováno v:
Journal of Psoriasis and Psoriatic Arthritis. 6:143-150
Background:Generalized pustular psoriasis (GPP) is a rare, severe neutrophilic skin disease with high unmet clinical need. The introduction of a GPP-specific International Classification of Diseases, 10thRevision (ICD-10), code has made it possible t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dafe78fe8ac53da22bb3e178fce001f2
https://doi.org/10.1177/24755303211021779
https://doi.org/10.1177/24755303211021779
Autor:
Daniel Saure, Jason E. Hawkes, Russel Burge, Melinda Gooderham, Missy McKean-Matthews, Stephanie Strakbein, Kyoungah See, Craig L. Leonardi
Publikováno v:
Dermatology and Therapy
Introduction Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is an approved treatment for plaque psoriasis. This study aimed to use animated visualizations as a tool to simplify complex data from ixekizumab c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffe9b292cc5e556546f5ebf0ae8d52c4
https://doi.org/10.1007/s13555-021-00548-2
https://doi.org/10.1007/s13555-021-00548-2
Autor:
Ying Zhang, Lotus Mallbris, Missy McKean-Matthews, Gaia Gallo, Craig L. Leonardi, Russel Burge, Kyoungah See, Orin Goldblum
Publikováno v:
Dermatology and Therapy
Introduction Psoriasis Area Severity Index (PASI) assessment is complex and time-consuming. A simpler assessment measure more sensitive to changes in symptom severity and predictive of patients’ quality of life (Dermatology Life Quality Index, DLQI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::673c3f00dc4cce030c7851ef7c5b7a1d
https://doi.org/10.1007/s13555-021-00544-6
https://doi.org/10.1007/s13555-021-00544-6
Autor:
Craig L. Leonardi, Lena Lemke, Sohaib Hachaichi, Alison Balfour, Julia Jauch-Lembach, Norman Gaylis, Ines Brueckmann, Teodora Festini, Andrew Blauvelt, Piotr Wiland
Publikováno v:
Biodrugs
Background SDZ-ADL (GP2017; Sandoz GmbH, Austria) is an EMA-/FDA-approved adalimumab biosimilar. The effect of SDZ-ADL on quality of life (QoL) and patient-reported outcomes (PROs) was assessed as part of two phase III studies, one in patients with m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b429e4018b2ffd869924b21ef7b444e4
https://doi.org/10.1007/s40259-021-00470-1
https://doi.org/10.1007/s40259-021-00470-1
Publikováno v:
Journal of Psoriasis and Psoriatic Arthritis. 6:93-98
Background: Palmoplantar psoriasis can severely impact patient quality of life. Despite the influx of many new medications, it remains one of the most challenging psoriasis phenotypes to treat. Case Description: Herein, we present a case series of 7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::beae62f2539591b5cf9e7b6f70153216
https://doi.org/10.1177/2475530321995516
https://doi.org/10.1177/2475530321995516